ArticleBMC medical genomics2025
Molecular landscape of non-driver genes in myeloproliferative neoplasms through 333 cancer genes panel: Insights to reveal in Pakistan.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDiscoveries of driver mutations in myeloproliferative neoplasms (MPNs) have filled the diagnostic gap however there are non-driver genes which play an important role in the phenotype of the disease. This study is the first to evaluate the molecular landscape of non-driver genes in MPNs patients from Pakistan.
methodsA sample of fourteen MPNs patients (eight essential thrombocythemia, five primary myelofibrosis and one polycythemia vera) was investigated by the next generation sequencing, using 333 cancer genes panel. Chi square test was run in SPSS 22.0 to check association of non-driver genes with sub categories of MPNs.
resultAmong 333 oncology related genes, possible pathogenic variations were identified in 2.1% of analyzed genes (7/333). TP53 and KIT were the only known frequent non-driver genes in MPNs which were found mutated in this study. The highest frequency (85.7%) was found of UGT1 A1 gene variant *28 with 71.4% heterozygous (*1/*28) and 14.2% homozygous genotype (*28/*28). Second most common (64.2%) detected gene variants were of MTHFR with WT/c.1298A > C, c.1298A > C/c.1298A > C and c.677C > T/c.1298A > C genotypes 28.5%, 28.5% and 7.1%, respectively. Frequency of TP53 substitution c.215C > G was 57.1% and XRCC1 c.1196 A > G was 42.8%. KIT CNV was 42.8% whereas KIT substitution c.1924A > G was 7.1%. The frequency of DPYD *9A/c.496A > G/ IVS1 0-15 T > C and *2A/*9A/c.496A > G was 21.4%. The lowest frequency (7.1%) was observed of CYP2D6 *4/*41. KIT was significantly (P = 0.026) frequently mutated in primary myelofibrosis patients (4/5).
conclusionA distinct molecular landscape of non-driver genes was observed in MPNs from Pakistan and most of the genes detected belonged to drug metabolizing pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.